Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pieter C Smits

Showing results (121-130 of 186) with videos related to

Pageof 19
Sort By:
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 27, 2020
Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trialPieter C Smits, Chun Chin Chang, Bernard Chevalier, et al.
Lancet (London, England)|March 27, 2012
Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysisTullio Palmerini, Giuseppe Biondi-Zoccai, Diego Della Riva, et al.
The American Journal of Cardiology|February 22, 2005
Comparison of early outcome of percutaneous coronary intervention for unprotected left main coronary artery disease in the drug-eluting stent era with versus without intravascular ultrasonic guidancePierfrancesco Agostoni, Marco Valgimigli, Carlos A G Van Mieghem, et al.
Circulation|December 14, 2020
Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH TrialGeorgios J Vlachojannis, Jeroen M Wilschut, Rosanne F Vogel, et al.
Journal of the American College of Cardiology|October 1, 2011
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomesPatrick W Serruys, Yoshinobu Onuma, Dariusz Dudek, et al.
JACC. Cardiovascular Interventions|June 20, 2020
Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent GenerationPaul Guedeney, Bimmer E Claessen, Roxana Mehran, et al.
Circulation. Cardiovascular Interventions|October 11, 2012
First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality studyJohn A Ormiston, Patrick W Serruys, Yoshinobu Onuma, et al.
JAMA Cardiology|November 22, 2023
Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical TrialAntonio Landi, Mirvat Alasnag, Dik Heg, et al.
JACC. Cardiovascular Interventions|November 27, 2024
Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding RiskMarco Roffi, Antonio Landi, Dik Heg, et al.
JACC. Cardiovascular Interventions|December 20, 2014
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)Yoshinobu Onuma, Patrick W Serruys, Takashi Muramatsu, et al.
Pageof 19

Showing results (121-130 of 186) with videos related to

Sort By:
Pageof 19
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|May 27, 2020
Bioresorbable vascular scaffold versus metallic drug-eluting stent in patients at high risk of restenosis: the COMPARE-ABSORB randomised clinical trialPieter C Smits, Chun Chin Chang, Bernard Chevalier, et al.
Lancet (London, England)|March 27, 2012
Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysisTullio Palmerini, Giuseppe Biondi-Zoccai, Diego Della Riva, et al.
The American Journal of Cardiology|February 22, 2005
Comparison of early outcome of percutaneous coronary intervention for unprotected left main coronary artery disease in the drug-eluting stent era with versus without intravascular ultrasonic guidancePierfrancesco Agostoni, Marco Valgimigli, Carlos A G Van Mieghem, et al.
Circulation|December 14, 2020
Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH TrialGeorgios J Vlachojannis, Jeroen M Wilschut, Rosanne F Vogel, et al.
Journal of the American College of Cardiology|October 1, 2011
Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomesPatrick W Serruys, Yoshinobu Onuma, Dariusz Dudek, et al.
JACC. Cardiovascular Interventions|June 20, 2020
Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent GenerationPaul Guedeney, Bimmer E Claessen, Roxana Mehran, et al.
Circulation. Cardiovascular Interventions|October 11, 2012
First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality studyJohn A Ormiston, Patrick W Serruys, Yoshinobu Onuma, et al.
JAMA Cardiology|November 22, 2023
Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical TrialAntonio Landi, Mirvat Alasnag, Dik Heg, et al.
JACC. Cardiovascular Interventions|November 27, 2024
Abbreviated or Standard Antiplatelet Therapy After PCI in Diabetic Patients at High Bleeding RiskMarco Roffi, Antonio Landi, Dik Heg, et al.
JACC. Cardiovascular Interventions|December 20, 2014
Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions)Yoshinobu Onuma, Patrick W Serruys, Takashi Muramatsu, et al.
Pageof 19